Alcon AG vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Alcon AG trades at $75 (market cap $36.44B), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Alcon AG pays a 0.48% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | QYLD | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.12 | $18.52 |
52-Week Low | $62.02 | $16.46 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
QYLD trades at $18.18, up 0.14% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a high distribution yield near 12% through covered call strategies on the Nasdaq-100, though historical data shows it has underperformed the index in strong bull markets. Recent dividends include $0.18 and $0.19 payouts in mid-2026.
Outlook is mixed: QYLD provides substantial income for risk-averse investors in sideways markets, but caps upside potential. Key risks include erosion of net asset value during rallies and competition from lower-fee alternatives. Analyst sentiment is divided, with some upgrades highlighting yield appeal amid volatility.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →